Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure

International Journal of Cardiology

Volumn 203, Issue , 2016, Pages 909-915

  Lopatin, Yuri M ^a   Rosano, Giuseppe M C ^b,c   Fragasso, Gabriele ^d   Lopaschuk, Gary D ^e   Seferovic, Petar M ^f   Gowdak, Luis Henrique W ^g   Vinereanu, Dragos ^h   Hamid, Magdy Abdel ⁱ   Jourdain, Patrick ^j   Ponikowski, Piotr ^k  

^a VOLGOGRAD STATE MEDICAL UNIVERSITY   (Russian Federation)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY OF BELGRADE   (Serbia)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

ⁱ CAIRO UNIVERSITY   (Egypt)

^j CENTRE HOSPITALIER RENÉ DUBOS   (France)

^k WROCLAW MEDICAL UNIVERSITY   (Poland)

more..

Author keywords

Cardiac energy metabolism; Heart failure; Trimetazidine

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE PHOSPHATE; TRIMETAZIDINE; VASODILATOR AGENT;

ALL CAUSE MORTALITY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENERGY METABOLISM; EVENT FREE SURVIVAL; FATTY ACID OXIDATION; GLUCOSE OXIDATION; GLYCOLYSIS; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE METABOLISM; HOSPITALIZATION; HUMAN; ISCHEMIC CARDIOMYOPATHY; LONG TERM CARE; META ANALYSIS (TOPIC); MORTALITY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTING ENERGY EXPENDITURE; REVIEW; SURVIVAL; SURVIVAL TIME; SYSTOLIC HEART FAILURE; CARDIAC MUSCLE; METABOLISM; PROGNOSIS; TREATMENT OUTCOME;

ENERGY METABOLISM; HEART FAILURE; HUMANS; MYOCARDIUM; PROGNOSIS; TREATMENT OUTCOME; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 84952803195     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.11.060     Document Type: Review

References (79)

1. A.L. Bui, T.B. Horwich, and G.C. Fonarow Epidemiology and risk profile of heart failure Nat. Rev. Cardiol. 8 2011 30 41
2. D. Lloyd-Jones, R.J. Adams, T.M. Brown, M. Carnethon, S. Dai, G. De Simone, and et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association Circulation 121 2010 e46 e215
3. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 Eur. Heart J. 33 2012 1787 1847
4. W. Doehner, M. Frenneaux, and S.D. Anker Metabolic impairment in heart failure: the myocardial and systemic perspective J. Am. Coll. Cardiol. 64 2014 1388 1400
5. G. Heusch, P. Libby, B. Gersh, D. Yellon, M. Bohm, G. Lopaschuk, and et al. Cardiovascular remodelling in coronary artery disease and heart failure Lancet 383 2014 1933 1943
6. Y. Lopatin Metabolic cardiac protection is beneficial in patients undergoing coronary revascularization: is it necessary afterwards? Heart Metab. 58 2013 25 30
7. H. Xu, W. Zhang, Y. Zhou, Z. Zhou, H. Ma, B. Hu, and et al. Effects of trimetazidine therapy on left ventricular function after percutaneous coronary intervention Chin. J. Cardiol. 41 2013 205 209
8. N. Zhang, J. Lei, Q. Liu, W. Huang, H. Xiao, and H. Lei The effectiveness of preoperative trimetazidine on myocardial preservation in coronary artery bypass graft patients: a systematic review and meta-analysis Cardiology 131 2015 86 96
9. P. Di Napoli, A.A. Taccardi, and A. Barsotti Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy Heart 91 2005 161 165
10. G. Fragasso, A. Palloshi, P. Puccetti, C. Silipigni, A. Rossodivita, M. Pala, and et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor in patients with heart failure J. Am. Coll. Cardiol. 48 2006 992 998
11. H. Tuunanen, E. Engblom, A. Naum, K. Nagren, M. Scheinin, B. Hesse, and et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy Circulation 118 2008 1250 1258
12. G.D. Lopaschuk, J.R. Ussher, C.D. Folmes, J.S. Jaswal, and W.C. Stanley Myocardial fatty acid metabolism in health and disease Physiol. Rev. 90 2010 207 258
13. S. Neubauer The failing heart - an engine out of fuel N. Engl. J. Med. 356 2007 1140 1151
14. J.S. Ingwall, and R.G. Weiss Is the failing heart energy starved? On using chemical energy to support cardiac function Circ. Res. 95 2004 135 145
15. M. Beer, T. Seyfarth, J. Sandstede, W. Landschutz, C. Lipke, H. Kostler, and et al. Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)p-sloop magnetic resonance spectroscopy J. Am. Coll. Cardiol. 40 2002 1267 1274
16. M.A. Conway, J. Allis, R. Ouwerkerk, T. Niioka, B. Rajagopalan, and G.K. Radda Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31p magnetic resonance spectroscopy Lancet 338 1991 973 976
17. M.F. Allard, P.G. Emanuel, J.A. Russell, S.P. Bishop, S.B. Digerness, and P.G. Anderson Preischemic glycogen reduction or glycolytic inhibition improves postischemic recovery of hypertrophied rat hearts Am. J. Physiol. 267 1994 H66 H74
18. M. Rajabi, C. Kassiotis, P. Razeghi, and H. Taegtmeyer Return to the fetal gene program protects the stressed heart: a strong hypothesis Heart Fail. Rev. 12 2007 331 343
19. T. Kato, S. Niizuma, Y. Inuzuka, T. Kawashima, J. Okuda, Y. Tamaki, and et al. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure Circ. Heart Fail. 3 2010 420 430
20. M.F. Allard, B.O. Schonekess, S.L. Henning, D.R. English, and G.D. Lopaschuk Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts Am. J. Physiol. 267 1994 H742 H750
21. S.L. Henning, R.B. Wambolt, B.O. Schonekess, G.D. Lopaschuk, and M.F. Allard Contribution of glycogen to aerobic myocardial glucose utilization Circulation 93 1996 1549 1555
22. M.A. Schroeder, A.Z. Lau, A.P. Chen, Y. Gu, J. Nagendran, J. Barry, and et al. Hyperpolarized (13)c magnetic resonance reveals early- and late-onset changes to in vivo pyruvate metabolism in the failing heart Eur. J. Heart Fail. 15 2013 130 140
23. L. Zhang, J.S. Jaswal, J.R. Ussher, S. Sankaralingam, C. Wagg, M. Zaugg, and et al. Cardiac insulin resistance and decreased mitochondrial energy production precede the development of systolic heart failure following pressure overload hypertrophy Circulation: Heart Fail. 6 2013 1039 1048
24. P. Zhabyeyev, M. Gandhi, J. Mori, R. Basu, Z. Kassiri, A. Clanachan, and et al. Pressure-overload-induced heart failure induces a selective reduction in glucose oxidation at physiological afterload Cardiovasc. Res. 97 2013 676 685
25. J. Mori, O.A. Alrob, C.S. Wagg, R.A. Harris, G.D. Lopaschuk, and G.Y. Oudit ANG II causes insulin resistance and induces cardiac metabolic switch and inefficiency: a critical role of pdk4 Am. J. Physiol. Heart Circ. Physiol. 304 2013 H1103 H1113
26. J. Mori, R. Basu, B.A. McLean, S.K. Das, L. Zhang, V.B. Patel, and et al. Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction Circ. Heart Fail. 5 2012 493 503
27. B. Liu, A.S. Clanachan, R. Schulz, and G.D. Lopaschuk Cardiac efficiency is improved after ischemia by altering both the source and fate of protons Circ. Res. 79 1996 940 948
28. Q. Liu, J.C. Docherty, J.C. Rendell, A.S. Clanachan, and G.D. Lopaschuk High levels of fatty acids delay the recovery of intracellular ph and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation J. Am. Coll. Cardiol. 39 2002 718 725
29. R.M. Bersin, C. Wolfe, M. Kwasman, D. Lau, C. Klinski, K. Tanaka, and et al. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate J. Am. Coll. Cardiol. 23 1994 1617 1624
30. P.J. Randle, P.B. Garland, C.N. Hales, and E.A. Newsholme The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus Lancet 1 1963 785 789
31. G.M. Reaven, H. Chang, and B.B. Hoffman Additive hypoglycemic effects of drugs that modify free-fatty acid metabolism by different mechanisms in rats with streptozocin-induced diabetes Diabetes 37 1988 28 32
32. M. Turcani, and H. Rupp Etomoxir improves left ventricular performance of pressure-overloaded rat heart Circulation 96 1997 3681 3686
33. S. Schmidt-Schweda, and C. Holubarsch First clinical trial with etomoxir in patients with chronic congestive heart failure Clin. Sci. (Lond.) 99 2000 27 35
34. K. Abozguia, P. Elliott, W. McKenna, T.T. Phan, G. Nallur-Shivu, I. Ahmed, and et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy Circulation 122 2010 1562 1569
35. L. Lee, R. Campbell, M. Scheuermann-Freestone, R. Taylor, P. Gunaruwan, L. Williams, and et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment Circulation 112 2005 3280 3288
36. J.F. Cheng, M. Chen, D. Wallace, S. Tith, M. Haramura, B. Liu, and et al. Synthesis and structure-activity relationship of small-molecule malonyl coenzyme a decarboxylase inhibitors J. Med. Chem. 49 2006 1517 1525
37. J.R. Dyck, J.F. Cheng, W.C. Stanley, R. Barr, M.P. Chandler, S. Brown, and et al. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation Circ. Res. 94 2004 78 84
38. A. Al-Hesayen, E.R. Azevedo, J.S. Floras, S. Hollingshead, G.D. Lopaschuk, and J.D. Parker Selective versus nonselective beta-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization Eur. J. Heart Fail. 7 2005 618 623
39. P.F. Kantor, A. Lucien, R. Kozak, and G.D. Lopaschuk The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme a thiolase Circ. Res. 86 2000 580 588
40. G.D. Lopaschuk, R. Barr, P.D. Thomas, and J.R. Dyck Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase Circ. Res. 93 2003 33 37
41. R. Saeedi, M. Grist, R.B. Wambolt, A. Bescond-Jacquet, A. Lucien, and M.F. Allard Trimetazidine normalizes postischemic function of hypertrophied rat hearts J. Pharmacol. Exp. Ther. 314 2005 446 454
42. G. Fragasso, F. De Cobelli, G. Perseghin, A. Esposito, A. Palloshi, G. Lattuada, and et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure Eur. Heart J. 27 2006 942 948
43. K.H. Park, W.J. Park, M.K. Kim, D.W. Park, J.H. Park, H.S. Kim, and et al. Effects of trimetazidine on endothelial dysfunction after sheath injury of radial artery Am. J. Cardiol. 105 2010 1723 1727
44. J.F. Renaud Internal pH, Na +, and Ca2 + regulation by trimetazidine during cardiac cell acidosis Cardiovasc. Drugs Ther. 1 1988 677 686
45. I. Maridonneau-Parini, and C. Harpey Effects of trimetazidine on membrane damage induced by oxygen free radicals in human red cells Br. J. Clin. Pharmacol. 20 1985 148 151
46. M. Khan, S. Meduru, M. Mostafa, S. Khan, K. Hideg, and P. Kuppusamy Trimetazidine, administered at the onset of reperfusion, ameliorates myocardial dysfunction and injury by activation of p38 mitogen-activated protein kinase and Akt signaling J. Pharmacol. Exp. Ther. 333 2010 421 429
47. X. Liu, Y. Gai, F. Liu, W. Gao, Y. Zhang, M. Xu, and et al. Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidase-ROS-CTGF pathway Cardiovasc. Res. 88 2010 150 158
48. J. Lommi, M. Kupari, and H. Yki-Järvinen Free fatty acid kinetics and oxidation in congestive heart failure Am. J. Cardiol. 81 1998 45 50
49. G. Fragasso, A. Salerno, G. Lattuada, A. Cuko, G. Calori, A. Scollo, and et al. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure Heart 97 2011 1495 1500
50. L. Brottier, J.L. Barat, C. Combe, B. Boussens, J. Bonnet, and H. Bricaud Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy Eur. Heart J. 11 1990 207 212
51. C. Lu, P. Dabrowski, G. Fragasso, and S.L. Chierchia Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease Am. J. Cardiol. 82 1998 898 901
52. R. Belardinelli, and A. Purcaro Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy Eur. Heart J. 22 2001 2164 2170
53. G. Fragasso, P.M. Piatti, L. Monti, A. Palloshi, E. Setola, P. Puccetti, and et al. Short- and long-term beneficial effects of partial free fatty acid inhibition in diabetic patients with ischemic dilated cardiomyopathy Am. Heart J. 146 2003 1 8
54. L.D. Monti, E. Setola, G. Fragasso, R.P. Camisasca, P. Lucotti, E. Galluccio, and et al. Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy Am. J. Physiol. Endocrinol. Metab. 290 2006 E54 E59
55. G.M.C. Rosano, C. Vitale, B. Sposato, G. Mercuro, and M. Fini Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study Cardiovasc. Diabetol. 2 2003 1 9
56. C. Vitale, M. Wajngaten, B. Sposato, O. Gebara, P. Rossini, M. Fini, and et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease Eur. Heart J. 25 2004 1814 1821
57. H. Sisakian, A. Torgomyan, and A. Barkhudaryan The effect of trimetazidine on left ventricular systolic function and physical tolerance in patients with ischaemic cardiomyopathy Acta Cardiol. 62 2007 493 499
58. P. Di Napoli, P. Di Giovanni, M.A. Gaeta, G. D'Apolito, and A. Barsotti Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy Am. Heart J. 154 2007 e1 e5 (602)
59. R. Belardinelli, M. Solenghi, L. Volpe, and A. Purcaro Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect Eur. Heart J. 28 2007 1102 1108
60. P. Zhao, J. Zhang, X.G. Yin, P. Maharaj, S. Narraindoo, L.Q. Cui, and et al. The effect of trimetazidine on cardiac function in diabetic patients with idiopathic dilated cardiomyopathy Life Sci. 92 2013 633 638
61. T. El-Kady, K. El-Sabban, M. Gabaly, A. Sabry, and S. Abdel-Hady Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study Am. J. Cardiovasc. Drugs 5 2005 271 278
62. P. Di Napoli, P. Di Giovanni, M.A. Gaeta, A.A. Taccardi, and A. Barsotti Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo trimetazidine trial J. Cardiovasc. Pharmacol. 50 2007 585 589
63. G. Fragasso, G. Rosano, S.H. Baek, H. Sisakian, P. Di Napoli, L. Alberti, and et al. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicenter retrospective cohort study Int. J. Cardiol. 163 2013 320 325
64. D. Gao, N. Ning, X. Niu, G. Hao, and Z. Meng Trimetazidine: a meta-analysis of randomised controlled trials in heart failure Heart 97 2011 278 286
65. L. Zhang, Y. Lu, H. Jiang, L. Zhang, A. Sun, Y. Zou, and et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis J. Am. Coll. Cardiol. 59 2012 913 922
66. X. Zhou, and J. Chen Is treatment with trimetazidine beneficial in patients with chronic heart failure? PLoS ONE 9 2014 e94660
67. S. Grajek, and M. Michalak The effect of trimetazidine added to pharmacological treatment on all-cause mortality in patients with systolic heart failure Cardiology 131 2015 22 29
68. S. Masson, R. Latini, I.S. Anand, S. Barlera, L. Angelici, T. Vago, and et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan heart failure trial) J. Am. Coll. Cardiol. 52 2008 997 1003
69. M. Wong, L. Staszewsky, R. Latini, S. Barlera, A. Volpi, Y.T. Chiang, and et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study J. Am. Coll. Cardiol. 40 2002 970 975
70. I. Ekman, J.G. Cleland, B. Andersson, and K. Swedberg Exploring symptoms in chronic heart failure Eur. J. Heart Fail. 7 2005 699 703
71. M. Packer, K.A. Narahara, U. Elkayam, J.M. Sullivan, D.L. Pearle, B.M. Massie, and et al. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study J. Am. Coll. Cardiol. 22 1993 65 72
72. K. Swedberg, M. Komajda, M. Bohm, J.S. Borer, I. Ford, A. Dubost-Brama, and et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study Lancet 376 2010 875 885
73. K. Fox, I. Ford, P.G. Steg, M. Tendera, and R. Ferrari Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial Lancet 372 2008 807 816
74. J.N. Cohn, D.G. Archibald, S. Ziesche, J.A. Franciosa, W.E. Harston, F.E. Tristani, and et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study N. Engl. J. Med. 314 1986 1547 1552
75. J.N. Cohn, G. Johnson, S. Ziesche, F. Cobb, G. Francis, F. Tristani, and et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure N. Engl. J. Med. 325 1991 303 310
76. A.L. Taylor, S. Ziesche, C. Yancy, P. Carson, R. D'Agostino Jr., K. Ferdinand, and et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure N. Engl. J. Med. 351 2004 2049 2057
77. M. Packer, C.M. O'Connor, J.K. Ghali, M.L. Pressler, P.E. Carson, R.N. Belkin, and et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective randomized amlodipine survival evaluation study group N. Engl. J. Med. 335 1996 1107 1114
78. H.C. Wijeysundera, M.S. Hansen, E. Stanton, A.S. Cropp, C. Hall, N.S. Dhalla, and et al. Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine Am. Heart J. 146 2003 291 297
79. N. Danchin, M. Marzilli, A. Parkhomenko, and J.P. Ribeiro Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis Cardiology 120 2011 59 72